Literature DB >> 21258055

Clinical characteristics and outcomes of critically ill cancer patients with septic shock.

S A Ñamendys-Silva1, M O González-Herrera, J Texcocano-Becerra, A Herrera-Gómez.   

Abstract

OBJECTIVE: To evaluate the clinical characteristics and outcomes of critically ill cancer patients with septic shock.
DESIGN: Prospective, observational cohort study.
METHODS: Medical-surgical intensive care unit (ICU) at the Instituto Nacional de Cancerología located in Mexico City from January 2008 to February 2010. There were no interventions. Eighty-two consecutive cancer patients with septic shock aged over 18 years were prospectively included and evaluated.
RESULTS: During the study period, 620 critically ill cancer patients were admitted to ICU. Ninety-four patients were evaluated for septic shock at the request of ward onco-hematologists or surgeon oncologist responsible for the patient. After being evaluated by the intensivists, 82 patients were admitted to the ICU. Of the 82 patients, 56 (68.3%) had solid tumours and 26 (31.7%) had hematological malignancy. The most frequent sites of infection were: abdominal (57.3%) and respiratory (35.8%). Cultures were positive in 41 (50%) patients. The 63.4% of the patients had three or more organ dysfunctions on the day of their admission to the ICU. Cox multivariate analysis identified the Sequential Organ Failure Assessment (SOFA) score [hazard ratio (HR): 1.11; 95% confidence interval (95% CI): 1.02-1.19, P=0.008) and performance status (PS)≥2 (HR: 1.84; 95% CI: 1.03-3.29, P=0.040) as independent predictors of death to 3 months. The ICU mortality rate was 41.5% (95% CI: 31-52%).
CONCLUSION: The variables associated with increased mortality were the degree of organ dysfunction determined by SOFA score at ICU admission and PS≥2.
© The Author 2011. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21258055     DOI: 10.1093/qjmed/hcq260

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  7 in total

1.  Outcomes of critically ill cancer patients with Acinetobacter baumannii infection.

Authors:  Silvio A Ñamendys-Silva; Paulina Correa-García; Francisco J García-Guillén; María O González-Herrera; Américo Pérez-Alonso; Julia Texcocano-Becerra; Angel Herrera-Gómez; Patricia Cornejo-Juárez; Abelardo Meneses-García
Journal:  World J Crit Care Med       Date:  2015-08-04

Review 2.  Survival in solid cancer patients following intensive care unit admission.

Authors:  Kathryn Puxty; Philip McLoone; Tara Quasim; John Kinsella; David Morrison
Journal:  Intensive Care Med       Date:  2014-09-16       Impact factor: 17.440

3.  Acute respiratory distress syndrome caused by influenza B virus infection in a patient with diffuse large B-cell lymphoma.

Authors:  Silvio A Namendys-Silva; María O González-Herrera; Julia Texcocano-Becerra; Angel Herrera-Gómez
Journal:  Case Rep Med       Date:  2011-10-29

4.  Usefulness of qSOFA and ECOG Scores for Predicting Hospital Mortality in Postsurgical Cancer Patients without Infection.

Authors:  Silvio A Ñamendys-Silva; Emerson Joachin-Sánchez; Aranza Joffre-Torres; Bertha M Córdova-Sánchez; Guadalupe Ferrer-Burgos; Octavio González-Chon; Angel Herrera-Gomez
Journal:  Int J Chronic Dis       Date:  2019-05-02

5.  Impact of critical care response team implementation on oncology patient outcomes: A retrospective cohort study.

Authors:  Saad Al Qahtani; Ali Alaklabi; Aiman El-Saed
Journal:  Int J Crit Illn Inj Sci       Date:  2020-09-16

6.  Higher cut-off serum procalcitonin level for sepsis diagnosis in metastatic solid tumor patients.

Authors:  Segal Abdul Aziz; Erni Juwita Nelwan; Lugyanti Sukrisman; Suhendro Suhendro
Journal:  BMC Res Notes       Date:  2018-01-30

7.  Outcome of Critically Ill Patients with Testicular Cancer.

Authors:  Silvio A Ñamendys-Silva; Mireya Barragán-Dessavre; Andoreni R Bautista-Ocampo; Francisco J García-Guillén; Bertha M Córdova-Sánchez; Edgar Constantino-Hérnandez; Paulina Correa-García; Octavio González-Chon; Angel Herrera-Gómez
Journal:  Biomed Res Int       Date:  2017-10-26       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.